Vaginal Laser Therapy for GSM in Breast Cancer Survivors Lacks Consistent Proof of Benefit
Genitourinary syndrome of menopause remains a stubborn source of pain, dryness, and sexual dysfunction for many breast cancer survivors, especially during endocrine therapy. In this setting, clinicians have looked for nonhormonal options that might relieve symptoms without raising concern about estrogen exposure. Vaginal laser therapy has been marketed into that gap, but a modality-specific systematic review found that the evidence still does not support a reliable laser-specific benefit for the outcomes that matter most to patients: dyspareunia, intercourse-related dryness, and overall sexual function.
The review separated CO2 and Er:YAG devices rather than treating them as interchangeable technologies. That distinction matters because the physics and tissue effects differ, and clinical expectations should not be borrowed from one platform and applied to the other. Across five databases and trial registries searched through 22 August 2026, investigators identified 35 evidence reports representing 28 study families, including 19 CO2 studies, six Er:YAG studies alone, one Er:YAG plus Nd:YAG study versus Er:YAG alone, and two studies of other systems.
The overall pattern was familiar to anyone who has followed energy-based vaginal interventions: uncontrolled studies often looked encouraging early, while controlled trials were far less persuasive.
Sham-Controlled CO2 Trials Did Not Deliver a Reproducible Laser Signal
Only two CO2 trials used sham controls. Neither produced a reproducible laser-specific improvement in dyspareunia or overall sexual function. One trial did show a favorable result for daily dryness and selected objective measures, but the same signal did not extend to intercourse-related dryness or painful sex, which are the symptoms most likely to drive treatment decisions in the clinic.
This split is clinically important. A therapy that improves a narrow measure of vaginal comfort but leaves the central pain and sexual-function endpoints unchanged cannot be assumed to have meaningful patient-level value. In a survivorship population already navigating endocrine-related mucosal change, symptom relief has to be durable, perceptible, and tied to daily function, not just to a laboratory-style surrogate or a transient improvement on a scale.
Active-comparator studies did not rescue the case for laser therapy. Across those trials, no consistent advantage emerged over the comparison treatments. Uncontrolled cohorts did better in the short term, but the gains weakened with follow-up, a pattern that fits a placebo-sensitive condition in which symptom scoring, patient expectations, and time itself can all influence the appearance of benefit.
Er:YAG Evidence Remains Thin and Indirect
Evidence for Er:YAG devices was even less mature. The review found that Er:YAG data relied mainly on active-comparator or uncontrolled studies, with one trial comparing Er:YAG plus Nd:YAG against Er:YAG alone. Direct comparative evidence between CO2 and Er:YAG was absent, so no one can responsibly claim superiority, equivalence, or a class effect.
The certainty ratings reflected that thin evidence base. For sham-controlled CO2 effects, certainty was low to very low. For Er:YAG versus hyaluronic acid, certainty was also very low. In practical terms, those ratings mean the estimate of benefit could shift substantially with better trials, and current findings should not be treated as a stable foundation for routine clinical adoption.
A larger number of CO2 studies did not translate into stronger evidence. Volume is not the same as validity, and a broader publication footprint does not solve the core problem when most studies are small, heterogeneous, and vulnerable to bias.
Safety Data Are Reassuring Only in the Short Term
No serious treatment-related adverse event was reported in the included studies. That is reassuring, but only within a narrow frame. The evidence was not sufficient to assess uncommon harms, delayed tissue injury, scarring, chronic pain, or problems that may emerge after repeated procedures or longer observation. For a vaginal intervention used in cancer survivorship, the absence of a serious event in published cohorts cannot be converted into a clean long-term safety claim.
The biologic appeal of laser therapy is easy to understand. Controlled thermal or photomechanical injury is supposed to stimulate remodeling, collagen reorganization, and improved mucosal health. In theory, that could help restore vaginal tissue resilience after estrogen deprivation. The clinical data in breast cancer survivors do not yet show that the mechanism consistently translates into meaningful, durable symptom relief. Short-term improvement without sustained separation from control conditions raises the possibility that nonspecific effects are carrying much of the apparent benefit.
What the Current Evidence Can and Cannot Support
The strongest conclusion from this review is narrow and direct: available evidence does not establish a consistent laser-specific benefit on the main patient-reported outcomes in breast cancer survivors with GSM. CO2 has the larger evidence base, but size alone does not prove greater efficacy. Er:YAG data remain too indirect to support a firm practice position, and no head-to-head trial has shown whether one modality performs better than the other.
For clinicians, that means vaginal laser therapy should not be presented as a proven substitute for other GSM approaches in breast cancer survivors. The absence of direct CO2-versus-Er:YAG comparisons leaves a major gap, especially because device characteristics are not interchangeable. Until better trials are available, any discussion of laser therapy has to be framed as investigational rather than definitive care.
Trial Design Gaps Leave the Durability Question Open
The durability problem may be the most consequential unresolved issue. Uncontrolled cohorts frequently report improvement soon after treatment, then lessening benefit over time. In a syndrome shaped by ongoing endocrine therapy, vaginal atrophy, and persistent mucosal fragility, transient response is not enough. Patients need to know whether repeated procedures are necessary, whether any gain persists beyond the short term, and whether symptom relief justifies cost, time, and procedural burden.
The review also exposes a broader problem in this field: heterogeneous devices, inconsistent comparators, and outcomes that do not always map cleanly onto daily experience. Pain with intercourse, vaginal dryness during sexual activity, and overall sexual function should remain the anchor points for future studies. Surrogate measures and isolated symptom scales cannot stand in for what patients actually feel.
Until direct comparative trials are done and follow-up extends well beyond the immediate post-treatment window, neither superiority nor equivalence can be inferred for CO2 and Er:YAG laser therapy in breast cancer survivors with GSM.